Wells Fargo raises Johnson & Johnson price target to $272
Wells Fargo analyst Larry Biegelsen maintained an Overweight rating on Johnson & Johnson (NYSE: JNJ) and raised the price target to $272 from $263, signaling confidence in the stock's performance.
*this image is generated using AI for illustrative purposes only.
Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on Johnson & Johnson (NYSE: JNJ) while raising the stock's price target to $272 from the previous $263. The adjustment reflects an updated valuation outlook for the healthcare conglomerate.
Rating and Price Target Update
The revised price target of $272 represents an increase from the prior target of $263. The Overweight rating indicates that the analyst expects the stock to outperform the broader market or its sector peers in the near term.
| Metric | Value |
|---|---|
| Rating | Overweight |
| Previous Price Target | $263 |
| New Price Target | $272 |
The decision to raise the target underscores confidence in Johnson & Johnson's business fundamentals and future earnings potential.
What specific factors drove the updated valuation outlook for Johnson & Johnson?
How might Johnson & Johnson's recent product launches impact its future earnings potential?
What are the key risks that could affect the stock's ability to reach the new price target?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
